PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer.
DelveInsight Report, “PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015” analyses that PD-1 and PD-L1 inhibitors are among the hottest and highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. According to the analysis, 34 drugs* are in pipeline. Focus of development is ma...
